Research peptides, ready for the bench. For laboratory and research use only.

Retatrutide (LY3437943) is a 39-residue fatty-acid-conjugated GLP-1 / GIP / glucagon triple-receptor agonist (~4,731 Da) referenced in published research on metabolic regulation, weight, and hepatic steatosis. Supplied as a 15mg lyophilised research vial — the larger-fill option in the Retatrutide lineup for studies preferring fewer reconstitutions.

The same GLP-1 / GIP / glucagon tri-agonist Retatrutide peptide at a 10mg fill — referenced in published research on energy balance, adiposity, and hepatic steatosis models. Compact vial size for shorter research runs.

Tesamorelin is a 44-residue GHRH analog (hGRF 1–44) with a trans-3-hexenoyl modification (~5,196 Da) referenced in published research on the growth-hormone / IGF-1 axis, visceral adipose tissue, and lipid metabolism. Supplied as a 10mg lyophilised research vial.

Nicotinamide adenine dinucleotide (NAD+) is the pyridine dinucleotide cofactor (~663 Da) that serves as a substrate for sirtuins, PARPs, and CD38, and is cited throughout mitochondrial, sirtuin-signalling, and aging research. Supplied as a high-fill 1000mg lyophilised research vial for extended study runs.

TB-500 is the 17-residue acetylated actin-binding fragment of thymosin β-4 (~1,889 Da). Widely referenced in published in-vitro and animal-model research on wound healing, tendon and ligament repair, and cardiac remodelling. Supplied as a 10mg lyophilised research vial.

BPC-157 ("body protection compound") is a 15-residue stable gastric pentadecapeptide (~1,419 Da) heavily cited in rodent research on gastrointestinal mucosal healing, tendon and ligament repair, and angiogenesis. Notable in the literature for unusual acid stability. Supplied as a 10mg lyophilised research vial.

GHK-Cu is the copper-bound tripeptide Gly-His-Lys complexed with Cu²⁺ (~403 Da as the copper complex, ~340 Da as the peptide). Extensively referenced in research on skin remodelling, fibroblast gene expression, hair-follicle models, and anti-fibrotic pathways. Supplied as a generous 100mg lyophilised research vial — double the fill of most AU competitors' 50mg SKUs.

A co-lyophilised dual-pathway GH secretagogue blend: CJC-1295 no-DAC (30-residue GHRH analog, ~3,368 Da) alongside Ipamorelin (5-residue selective ghrelin/GHS-R agonist, ~711 Da). Referenced in published GH and IGF-1 pulsatility research. Ipamorelin is noted for minimal cortisol / prolactin response compared with earlier GHRPs.

MOTS-c is a 16-residue mitochondrial-derived peptide (~2,174 Da) encoded within the 12S rRNA ORF. Widely studied as an AMPK-activating exercise-mimetic and as a modulator of insulin sensitivity and mitochondrial homeostasis in aging research. Supplied as a 10mg lyophilised research vial.

The Klow blend co-lyophilises four research peptides referenced for repair and anti-inflammatory pathways in published in-vitro and animal studies: KPV (α-MSH C-terminal tripeptide), BPC-157 (pentadecapeptide), TB-500 (Tβ4 17-mer fragment), and GHK-Cu (copper tripeptide). Supplied at a total 80mg fill — materially below the à-la-carte component cost.

KPV is the Lys-Pro-Val C-terminal tripeptide fragment of α-MSH (~342 Da), referenced in published research on intestinal inflammation (colitis / IBD models), mast-cell activation, and mucosal healing. Acts through intracellular anti-inflammatory pathways independent of melanocortin receptors. Supplied as a 10mg lyophilised research vial.

Companion research-supply pack: one sterile syringe and alcohol prep wipes. Sold as a consumable add-on for handling and reconstitution research workflows alongside lyophilised vials. For laboratory and research use only.